Martin van Cleeff

1.5k total citations
9 papers, 512 citations indexed

About

Martin van Cleeff is a scholar working on Epidemiology, Microbiology and Molecular Biology. According to data from OpenAlex, Martin van Cleeff has authored 9 papers receiving a total of 512 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Epidemiology, 4 papers in Microbiology and 2 papers in Molecular Biology. Recurrent topics in Martin van Cleeff's work include Pneumonia and Respiratory Infections (5 papers), Respiratory viral infections research (4 papers) and Bacterial Infections and Vaccines (4 papers). Martin van Cleeff is often cited by papers focused on Pneumonia and Respiratory Infections (5 papers), Respiratory viral infections research (4 papers) and Bacterial Infections and Vaccines (4 papers). Martin van Cleeff collaborates with scholars based in United States, Germany and Italy. Martin van Cleeff's co-authors include Daniel A. Scott, Beate Schmöele-Thoma, William C. Gruber, Alejandra Gurtman, Emilio A. Emini, Lisa A. Jackson, Kathrin U. Jansen, Deepthi Jayawardene, Robert W. Frenck and John Treanor and has published in prestigious journals such as Vaccine, Radiation Research and Clinical and Vaccine Immunology.

In The Last Decade

Martin van Cleeff

9 papers receiving 492 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Martin van Cleeff United States 7 398 115 92 53 33 9 512
Chris Webber United States 16 586 1.5× 97 0.8× 163 1.8× 39 0.7× 26 0.8× 42 742
Rajeka Lazarus United Kingdom 11 329 0.8× 84 0.7× 79 0.9× 82 1.5× 22 0.7× 24 643
Kwang Nam Kim South Korea 10 124 0.3× 120 1.0× 51 0.6× 58 1.1× 23 0.7× 42 365
Mika Lahdenkari Finland 16 425 1.1× 59 0.5× 222 2.4× 75 1.4× 33 1.0× 31 549
Paola Canepa Italy 15 307 0.8× 64 0.6× 88 1.0× 52 1.0× 35 1.1× 29 404
Hoang M. Phan United States 7 383 1.0× 35 0.3× 108 1.2× 96 1.8× 7 0.2× 8 496
Jaclyn Bowman United Kingdom 7 293 0.7× 45 0.4× 97 1.1× 138 2.6× 16 0.5× 7 471
James O'Brien United States 11 251 0.6× 54 0.5× 42 0.5× 141 2.7× 13 0.4× 18 464
Alessandra Zappá Italy 15 400 1.0× 113 1.0× 29 0.3× 31 0.6× 27 0.8× 23 452
Eitaro Suzuki Japan 12 243 0.6× 120 1.0× 15 0.2× 33 0.6× 21 0.6× 41 362

Countries citing papers authored by Martin van Cleeff

Since Specialization
Citations

This map shows the geographic impact of Martin van Cleeff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin van Cleeff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin van Cleeff more than expected).

Fields of papers citing papers by Martin van Cleeff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin van Cleeff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin van Cleeff. The network helps show where Martin van Cleeff may publish in the future.

Co-authorship network of co-authors of Martin van Cleeff

This figure shows the co-authorship network connecting the top 25 collaborators of Martin van Cleeff. A scholar is included among the top collaborators of Martin van Cleeff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin van Cleeff. Martin van Cleeff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Schmöele-Thoma, Beate, Martin van Cleeff, Richard N. Greenberg, et al.. (2019). Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults. Human Vaccines & Immunotherapeutics. 15(3). 575–583. 6 indexed citations
2.
Frenck, Robert W., Anne Fiquet, Alejandra Gurtman, et al.. (2016). Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older. Vaccine. 34(30). 3454–3462. 21 indexed citations
3.
Bruyn, Guy de, David Workman, Richard Pollak, et al.. (2016). Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: A randomized Phase 2 clinical trial. Vaccine. 34(19). 2170–2178. 76 indexed citations
5.
Jackson, Lisa A., Alejandra Gurtman, Martin van Cleeff, et al.. (2013). Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine. 31(35). 3577–3584. 172 indexed citations
6.
Frenck, Robert W., Alejandra Gurtman, John Rubino, et al.. (2012). Randomized, Controlled Trial of a 13-Valent Pneumococcal Conjugate Vaccine Administered Concomitantly with an Influenza Vaccine in Healthy Adults. Clinical and Vaccine Immunology. 19(8). 1296–1303. 61 indexed citations
7.
Nasir, Adnan, et al.. (2011). Clinical evaluation of safety and efficacy of a new topical treatment for onychomycosis.. PubMed. 10(10). 1186–91. 4 indexed citations
8.
Cleeff, Martin van, et al.. (1989). Radiosensitivity of Parenchymal Hepatocytes as a Function of Oxygen Concentration. Radiation Research. 118(3). 488–488. 12 indexed citations
9.
Cleeff, Martin van, et al.. (1988). Radiation Sensitivity of Adult Human Parenchymal Hepatocytes. Radiation Research. 115(1). 152–152. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026